Boost Medical

Boost Medical is not just a medical device company, but an enterprise that sets industry standards. Through China's independent algorithm technology, it has solved common challenges in cardiovascular interventional diagnosis and treatment (how to quickly, cost-effectively, and accurately assess vascular function), and successfully brought this "China Solution" to the world stage, achieving a leap from "following" to "leading". Among them, the FAVOR III China prospective, multicenter, randomized controlled study, led by Fuwai Hospital and covering 26 top-tier hospitals across the country, showed that QFR-guided PCI can reduce the risk of major adverse cardiac events at 1 year by 35%, and the results were praised as "a remarkable RCT study in coronary physiology" and "a landmark clinical study". This technology is expected to rewrite global guidelines for the diagnosis and treatment of coronary artery disease.

1. QFR® Technology (Quantitative Flow Ratio): Revolutionary Innovation: A technology that calculates fractional flow reserve (FFR) based on routine coronary angiography images. It requires no pressure wire, no vasodilators (such as adenosine), and can complete assessment in just 3 minutes.
Solving Pain Points: It addresses the issues of high cost, complex operation, patient discomfort, and risk associated with traditional FFR measurement, transforming functional assessment from "optional" to "routine".
Accuracy: A large number of clinical studies (such as the FAVOR series) have demonstrated that its diagnostic accuracy is highly consistent with the gold standard wire-FFR (consistency > 90%).

2. Evidence-Based Medicine and "Dual Certification" of Guidelines
Boost Medical's products are not only implemented in China but have also gained recognition from the global academic community, which is a significant competitive advantage for medical device companies.
Included in Guidelines:
- China: Officially incorporated into the "Guidelines for Percutaneous Coronary Intervention (2025)", receiving a Class I, Level A recommendation, becoming a standard tool for guiding Chinese doctors in PCI decision-making.
- Europe: Included in the "2024 ESC Guidelines for the Management of Chronic Coronary Syndromes", marking broad recognition of China's independent technology by the European cardiology community.
Journal Publications: Relevant research results have been published multiple times in top journals such as The Lancet, JACC, and the European Heart Journal, building a solid academic barrier.

3. Product Matrix Upgrade: From "Single Function" to "Multimodal Integration"
Boost Medical is no longer limited to a single QFR technology, but has constructed a full-chain solution covering preoperative, intraoperative, and postoperative stages.
Multimodal Integration Technology (2025-2026 New Highlight):
At the 2025 Oriental Congress of Cardiology (OCC2025), Boost showcased CT angiography fusion technology and AI-enabled multimodal imaging solutions.
Achieved deep integration of QFR (functional) with IVUS/OCT (imaging). For example, its next-generation functional IVUS technology not only visualizes vascular structure but also simultaneously assesses blood flow function, providing "structure + function" dual precise diagnosis.
Pan-Vascular Layout: The technology platform has expanded from coronary arteries to cerebrovascular and peripheral vascular fields, aiming to become a platform-based enterprise for precise diagnosis in pan-vascular intervention.
Microcirculation and Plaque Assessment: Derived functions such as AMR (microcirculatory resistance index) and RWS® (vulnerable plaque assessment) help doctors identify high-risk plaques and microcirculatory disorders, enabling deeper treatment.

4. At Boost, we not only define products, but also define a way of working and growing. This is our common "Pulse":
• Passion: Intrinsic drive from within. We encourage every colleague to find the spark that creates value, making daily work energized by "truly making a difference".
• Uncompromised: Never compromise on science and quality. From algorithm accuracy to user experience, our pursuit of every detail is consistent.
• Learning: Growth is an eternal beta version. Whether it's deep learning of cutting-edge technology, clinical medical knowledge, or business and management wisdom, we provide a systematic learning platform and resources to help you build technical advantages and expert status.
• Simplicity: Simplification after deep insight. We advocate solving complex clinical problems with elegant and concise solutions, opposing unnecessary complexity.
• Empower: Enable everyone to become a better version of themselves and achieve each other's success. This is not just a concept, but an action we practice.

5. We are eager to find partners with genuine curiosity in scientific research and innovation, and a desire to create clinical impact in the medical device field. Whether you come from R&D, clinical, marketing, regulatory, or functional support, the following traits will make us a perfect match:
• Persistence in research and innovation: Possessing solid research foundations from doctoral studies, or practical experience in tackling tough challenges in related fields; not satisfied with the status quo, willing to challenge the "unexplored territories" of technology or business.
• Deep "user" empathy: Whether serving clinical doctors or end patients, deeply understand their core pain points and make this the starting point of all work.
• High identification with PULSE culture: Eager to work in an environment of passion, uncompromising quality, growth, simplicity, and empowerment, and willing to actively become a builder and disseminator of this culture.
• Responsibility and accountability: Dare to take responsibility for one's own projects, decisions, and team results, showing resilience in the pursuit of excellence.
• Embracing change and collaboration: In a rapidly developing innovative organization, be able to quickly adapt to change and willingly contribute wisdom in cross-functional teams to achieve win-win outcomes.